Stratum Biosciences Raises $2M Seed to Turn Skin Biology Into an AI-Driven Discovery Engine

Stratum Biosciences just pulled off the kind of seed round that makes a crowded market go quiet for a second and lean in. $2M is not the whole story. The real story is what got funded. Not another skin deep idea dressed up in biotech clothing, but a New York City company digging below the surface, into the actual biology of skin, where the signal is messier, richer, and a lot more valuable than the beauty aisle usually admits. In a world where plenty of people still confuse branding with science, Stratum Biosciences showed up with tissue, data, and receipts.

Founded in early 2024 and based at JLABS @ NYC in SoHo, Stratum Biosciences sits right at the intersection of artificial intelligence, dermatology research, and commercial skin innovation. Dr. Ross Lane Pearlman, Co-Founder and CEO, and Dr. Buu Duong, Co-Founder and President, did not build this around vague promises and glossy language. They built it around a proprietary biobank of more than 200,000 real skin tissue samples and an AI-powered discovery platform called SkinSync™. That name does some work, because sync is exactly the point. Biology, computation, and product development finally moving to the same rhythm instead of arguing in separate rooms.

That is what makes this seed round land with weight. Harvard Business School Alumni Angels of Greater New York and Skin Angels did not back a concept floating on caffeine and adjectives. They backed a company using biophysics-based molecular design and real biopsy-level data to uncover mechanisms in skin that conventional research keeps missing. Skin is the body’s largest organ, and somehow whole categories still treat it like expensive wallpaper. Stratum Biosciences is betting that if you understand how the barrier actually behaves across body sites, disease states, and clinical settings, you can build better actives, better formulations, and better outcomes without the usual smoke machine.

Over the past 12 months, Stratum Biosciences validated that thesis through partnerships with global CPG leaders and subsidiaries to develop novel composition-of-matter actives and formulations with optimized delivery systems and bioavailability. That line matters. Big partners do not open the door because a deck had nice gradients. They open it when the science can shorten the distance between discovery and something the market can use. Add in NVIDIA Inception support, a resident slot at Johnson and Johnson’s JLABS @ NYC, and research presented at the Innovations in Dermatological Sciences Conference at Rutgers, and the pattern gets harder to ignore.

There is also a leadership story here worth paying attention to. Dr. Ross Lane Pearlman brings deep clinical and cosmetic dermatology experience. Dr. Buu Duong brings the tissue-level diagnostic expertise of a board-certified dermatopathologist. Dr. David W. Osborne, Chief Scientific Officer, adds decades of formulation and topical drug development experience, including work tied to multiple FDA-approved therapies. That is not résumé confetti. That is a team built to translate skin biology into products that can matter in hyperpigmentation, skin longevity, rosacea, and eczema.

Congratulations to Dr. Ross Lane Pearlman, Dr. Buu Duong, Dr. David W. Osborne, and the entire Stratum Biosciences team, along with Harvard Business School Alumni Angels of Greater New York and Skin Angels. In biotech, everybody says they are looking for signal. Stratum Biosciences is literally mining it from skin, which feels less like a trend and more like the moment dermatology stopped guessing and started listening